A panel of experts that advises the FDA on vaccine decisions voted unanimously Thursday to approve booster doses of Moderna's COVID-19 vaccine.
The 19 members of the FDA's Vaccines and Related Biological Products Advisory Committee voted to authorize a 50-milligram dose — half the dose used in the primary series of shots — to boost immunity against COVID-19 at least 6 months after the second dose. Those who might need a booster are the same groups who've gotten a green light for third Pfizer doses. They include people:
Over age 65
Ages 18 to 64 who are at higher risk for severe COVID
Who are at higher risk of catching COVID because they live in group settings like nursing homes or prisons, or because they are frequently exposed at work, as health care workers are